Relmada Stock Surges 25% on Positive Cancer Trial Data

Positive Trial Data and Financing Boost Stock

Relmada Therapeutics, Inc. (NASDAQ:RLMD) shares increased 25% after the company announced positive 12-month interim data from its Phase 2 trial for NDV-01, a treatment for high-risk non-muscle invasive bladder cancer (NMIBC). The company also revealed a plan for a $160 million private financing.

Clinical Trial Overview

The study demonstrated a 12-month complete response (CR) rate of 76%, with the rate reaching 80% in the BCG-unresponsive patient group. The safety profile was favorable, with no Grade 3 or higher treatment-related adverse events reported. The most common adverse event was dysuria, affecting 54% of patients.

Economic and Market Impact

Relmada plans to advance NDV-01 into a Phase 3 trial in mid-2026, targeting a market of approximately 75,000 intermediate-risk patients annually in the U.S. To support development, the company is raising approximately $160 million through a private investment in public equity (PIPE) financing, selling shares at $4.75 each.

Summary

The combination of strong clinical results and significant new funding has driven investor confidence. The company's next major milestone will be the initiation of its Phase 3 program, with the current financing expected to close around March 11, 2026.

FAQ

Q: Why did Relmada Therapeutics' stock surge?
A: The stock surged 25% following the announcement of a 76% complete response rate in its Phase 2 bladder cancer drug trial and a new $160 million financing deal.

Q: What is the next step for Relmada's drug NDV-01?
A: The company plans to advance NDV-01 into a Phase 3 registrational program in mid-2026 to continue its evaluation for market approval.

Source: Investing.com